First attempt to produce experimental Campylobacter concisus infection in mice. 2008

Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
Department of Clinical Microbiology, National University Hospital (Rigshospitalet), Copenhagen, Denmark.

OBJECTIVE To infect mice with atypical Campylobacter concisus (C. concisus) for the first time. METHODS Three separate experiments were conducted in order to screen the ability of five clinical C. concisus isolates of intestinal origin and the ATCC 33237 type strain of oral origin to colonize and produce infection in immunocompetent BALB/cA mice. The majority of the BALB/cA mice were treated with cyclophosphamide prior to C. concisus inoculation to suppress immune functions. Inoculation of C. concisus was performed by the gastric route. RESULTS C. concisus was isolated from the liver, ileum and jejunum of cyclophosphamide-treated mice in the first experiment. No C. concisus strains were isolated in the two subsequent experiments. Mice infected with C. concisus showed a significant loss of body weight from day two through to day five of infection but this decreased at the end of the first week. Histopathological examination did not consistently find signs of inflammation in the gut, but occasionally microabscesses were found in the liver of infected animals. CONCLUSIONS Transient colonization with C. concisus was observed in mice with loss of body weight. Future studies should concentrate on the first few days after inoculation and in other strains of mice.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007583 Jejunum The middle portion of the SMALL INTESTINE, between DUODENUM and ILEUM. It represents about 2/5 of the remaining portion of the small intestine below duodenum. Jejunums
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002167 Campylobacter A genus of bacteria found in the reproductive organs, intestinal tract, and oral cavity of animals and man. Some species are pathogenic.
D002169 Campylobacter Infections Infections with bacteria of the genus CAMPYLOBACTER. Campylobacter Infection,Campylobacteriosis,Infections, Campylobacter,Campylobacterioses,Infection, Campylobacter
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
September 2021, Journal of infection in developing countries,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
November 2013, The Pediatric infectious disease journal,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
November 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
November 2008, FEMS immunology and medical microbiology,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
July 2013, Gut pathogens,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
April 2010, The FEBS journal,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
October 2001, Journal of clinical microbiology,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
February 2002, Journal of clinical microbiology,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
October 2005, European journal of gastroenterology & hepatology,
Rune Aabenhus, and Unne Stenram, and Leif Percival Andersen, and Henrik Permin, and Asa Ljungh
May 2012, Journal of medical microbiology,
Copied contents to your clipboard!